- Home
- MFIN vs DBVT Comparison
MFIN vs DBVT Comparison
Compare MFIN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- DBVT
- Stock Information
- Founded
- MFIN 1995
- DBVT 2002
- Country
- MFIN United States
- DBVT France
- Employees
- MFIN N/A
- DBVT N/A
- Industry
- MFIN Finance: Consumer Services
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFIN Finance
- DBVT Health Care
- Exchange
- MFIN Nasdaq
- DBVT Nasdaq
- Market Cap
- MFIN 207.3M
- DBVT 239.9M
- IPO Year
- MFIN 1996
- DBVT N/A
- Fundamental
- Price
- MFIN $9.17
- DBVT $8.35
- Analyst Decision
- MFIN
- DBVT Buy
- Analyst Count
- MFIN 0
- DBVT 4
- Target Price
- MFIN N/A
- DBVT $14.81
- AVG Volume (30 Days)
- MFIN 41.3K
- DBVT 102.2K
- Earning Date
- MFIN 07-29-2025
- DBVT 07-29-2025
- Dividend Yield
- MFIN 3.60%
- DBVT N/A
- EPS Growth
- MFIN N/A
- DBVT N/A
- EPS
- MFIN 1.60
- DBVT N/A
- Revenue
- MFIN $316,751,000.00
- DBVT $3,497,000.00
- Revenue This Year
- MFIN N/A
- DBVT $1,700.53
- Revenue Next Year
- MFIN $5.24
- DBVT $535.67
- P/E Ratio
- MFIN $5.73
- DBVT N/A
- Revenue Growth
- MFIN 13.91
- DBVT N/A
- 52 Week Low
- MFIN $6.48
- DBVT $2.21
- 52 Week High
- MFIN $10.50
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- MFIN 50.42
- DBVT 42.98
- Support Level
- MFIN $9.14
- DBVT $8.33
- Resistance Level
- MFIN $9.48
- DBVT $9.92
- Average True Range (ATR)
- MFIN 0.31
- DBVT 0.92
- MACD
- MFIN -0.02
- DBVT -0.32
- Stochastic Oscillator
- MFIN 44.83
- DBVT 4.53
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.